CFDE Data Portal | Search LEPROT

	Label	Description
	LEPROT Gene (Entity type)	ENSG00000213625 - leptin receptor overlapping transcript
	LEPROT associations Collection (Entity type)	Associations for LEPROT_associations
	LEPROT associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE168473 0 V 1 ISONIAZID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 2 V 5 PACLITAXEL HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE138789 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS

LEPROT

ENSG00000213625 - leptin receptor overlapping transcript

LEPROT associations

Associations for LEPROT_associations

LEPROT associations.tsv

A file from IDG as part of the Harmonizome project

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

A Gene Set from LINCS

GSE225869 1 V 0 TEMOZOLOMIDE HUMAN DN

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE168473 0 V 1 ISONIAZID HUMAN UP

A Gene Set from LINCS

GSE172016 2 V 5 PACLITAXEL HUMAN UP

A Gene Set from LINCS

GSE205729,GSE205731 2 V 3 TAZEMETOSTAT HUMAN UP

A Gene Set from LINCS

GSE138789 metformin 0 v 1 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.